Synthesis and antiviral evaluation of alkoxyalkyl derivatives of 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine against cytomegalovirus and orthopoxviruses

被引:53
作者
Beadle, JR
Wan, WB
Ciesla, SL
Keith, KA
Hartline, C
Kern, ER
Hostetler, KY [1 ]
机构
[1] Univ Calif San Diego, Dept Med, VA San Diego Healthcare Syst, La Jolla, CA 92093 USA
[2] Univ Alabama, Sch Med, Dept Pediat, Birmingham, AL 35233 USA
关键词
D O I
10.1021/jm050473m
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
9-(S)-(3-Hydroxy-2-phosphonomethoxypropyl)adenine [(S)-HPMPA] was one of the first acyclic nucleoside phosphonates described and has been reported to have good antiviral activity against most double-stranded DNA viruses, including the herpes group viruses and the orthopoxviruses. However, (S)-HPMPA is not orally bioavailable and has not been developed for clinical use. We have prepared orally bioavailable lipid esters of (S)-HPMPA and report their synthesis and antiviral evaluation against cytomegalovirus and orthopoxviruses. These esters were evaluated in vitro in cells infected with human cytomegalovirus (HCMV), murine cytomegalovirus (MCMV), vaccinia (VV), and cowpox viruses (CV). The most active compound, oleyloxyethyl-(S)-HPMPA, was found to have EC50 value of 0.003 mu M against HCMV vs 1.4 mu M for unmodified HPMPA. In cells infected with VV and CV, octadecyloxyethyl-(S)-HPMPA had EC50 values of 0.01-0.02 mu M versus 2.7 -4.0 mu M for unmodified HPMPA. When compared with the alkoxyalkyl esters of cidofovir, the corresponding alkoxyalkyl esters of (S)-HPMPA were equally active against HCMV and MCMV but were 15-20-fold more active against VV and CV in vitro. The alkoxyalkyl esters of (S)-HPMPA are promising new compounds worthy of further investigation for treatment of infections caused by herpes viruses and orthopoxviruses.
引用
收藏
页码:2010 / 2015
页数:6
相关论文
共 37 条
[1]   Increased antiviral activity of 1-O-hexadecyloxypropyl-[ 2-14C] cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism [J].
Aldern, KA ;
Ciesla, SL ;
Winegarden, KL ;
Hostetler, KY .
MOLECULAR PHARMACOLOGY, 2003, 63 (03) :678-681
[2]   Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections [J].
Baker, R ;
Bray, M ;
Huggins, JW .
ANTIVIRAL RESEARCH, 2003, 57 (1-2) :13-23
[3]   Synthesis and evaluation of novel amidate prodrugs of PMEA and PMPA [J].
Ballatore, C ;
McGuigan, C ;
De Clercq, E ;
Balzarini, J .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (08) :1053-1056
[4]   Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro [J].
Beadle, JR ;
Hartline, C ;
Aldern, KA ;
Rodriguez, N ;
Harden, E ;
Kern, ER ;
Hostetler, KY .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (08) :2381-2386
[5]   Disposition of the acyclic nucleoside phosphonate (S)-9(3-hydroxy-2-phosphonylmethoxypropyl)adenine [J].
Bijsterbosch, MK ;
Smeijsters, LJJW ;
van Berkel, TJC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (05) :1146-1150
[6]   Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model [J].
Buller, RM ;
Owens, G ;
Schriewer, J ;
Melman, L ;
Beadle, JR ;
Hostetler, KY .
VIROLOGY, 2004, 318 (02) :474-481
[7]   Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney [J].
Ciesla, SL ;
Trahan, J ;
Wan, WB ;
Beadle, JR ;
Aldern, KA ;
Painter, GR ;
Hostetler, KY .
ANTIVIRAL RESEARCH, 2003, 59 (03) :163-171
[8]  
Cundy KC, 1996, DRUG METAB DISPOS, V24, P745
[9]  
DECLERCQ E, 1987, ANTIVIR RES, V8, P261
[10]   A NOVEL SELECTIVE BROAD-SPECTRUM ANTI-DNA VIRUS AGENT [J].
DECLERCQ, E ;
HOLY, A ;
ROSENBERG, I ;
SAKUMA, T ;
BALZARINI, J ;
MAUDGAL, PC .
NATURE, 1986, 323 (6087) :464-467